Table 4.
Study | Number of women | Median follow up (mo) | Relative Risk of ER positive cancer | Population |
---|---|---|---|---|
IBIS-2 trial [32] * | 6,000 accrued | Recruitment Completed-Results Pending | Postmenopausal and high risk | |
MAP3 trial [33] ** | 4,560 | 35 | 0.35 (0.18-0.70) | Postmenopausal and high risk |
* 1.0 mg anastrozole a day for 5 years; ** 25 mg exemestane a day for 5 years.